• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: 10 synthetic peptides targeting 5 tumor asociated antigens
Date Designated: 01/23/2013
Orphan Designation: Treatment of non-small cell lung cancer in patients expressing HLA-A2
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Orphan Synergy Europe Pharma (OSE Pharma)
OSE Pharma Pepiniere Paris Sante Cochin
29 bis rue du faubourg Saint Jacques

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.